A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors

Farletuzumab is a humanized monoclonal antibody against folate receptor α (FRA). The purpose of the study is to assess safety and tolerability, the pharmacokinetic (PK) profile, and preliminary antitumor effect. Patients with ovarian cancer (OC) or FRA-expressing solid tumors who are resistant to st...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Invest New Drugs
Main Authors: Sasaki, Yasutsuna, Miwa, Keisuke, Yamashita, Keishi, Sunakawa, Yu, Shimada, Ken, Ishida, Hiroo, Hasegawa, Kosei, Fujiwara, Keiichi, Kodaira, Makoto, Fujiwara, Yasuhiro, Namiki, Masayuki, Matsuda, Minami, Takeuchi, Yutaka, Katsumata, Noriyuki
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2014
Teme:
Phase I Studies
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4387250/
https://ncbi.nlm.nih.gov/pubmed/25380636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0180-8
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki